HK1037517A1 - Use of apomorphine in the treatment of premature ejaculation - Google Patents
Use of apomorphine in the treatment of premature ejaculationInfo
- Publication number
- HK1037517A1 HK1037517A1 HK01106459A HK01106459A HK1037517A1 HK 1037517 A1 HK1037517 A1 HK 1037517A1 HK 01106459 A HK01106459 A HK 01106459A HK 01106459 A HK01106459 A HK 01106459A HK 1037517 A1 HK1037517 A1 HK 1037517A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- apomorphine
- treatment
- premature ejaculation
- ejaculation
- premature
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/086,630 US6403605B1 (en) | 1998-05-29 | 1998-05-29 | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
PCT/CA1999/000508 WO1999062502A2 (en) | 1998-05-29 | 1999-05-28 | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1037517A1 true HK1037517A1 (en) | 2002-02-15 |
Family
ID=22199842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01106459A HK1037517A1 (en) | 1998-05-29 | 2001-09-12 | Use of apomorphine in the treatment of premature ejaculation |
Country Status (11)
Country | Link |
---|---|
US (3) | US6403605B1 (xx) |
EP (2) | EP1082118B1 (xx) |
AR (1) | AR019579A1 (xx) |
AT (1) | ATE326969T1 (xx) |
AU (1) | AU764009B2 (xx) |
CA (1) | CA2331387A1 (xx) |
DE (1) | DE69931487T2 (xx) |
ES (1) | ES2268869T3 (xx) |
HK (1) | HK1037517A1 (xx) |
TW (1) | TWI232748B (xx) |
WO (1) | WO1999062502A2 (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
CA2522231A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
WO2005107810A2 (en) | 2004-05-11 | 2005-11-17 | Emotional Brain B.V. | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
KR20150089085A (ko) * | 2007-02-12 | 2015-08-04 | 브릭스 파마슈티컬스 인코퍼레이티드 | 조루 및 발기부전을 동시에 치료하는 방법 |
WO2008100933A2 (en) * | 2007-02-12 | 2008-08-21 | Dmi Biosciences, Inc. | Reducing side effects of tramadol |
US20110150946A1 (en) * | 2008-08-22 | 2011-06-23 | Al-Ghananeem Abeer M | Transdermal Delivery of Apomorphine Using Microneedles |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2818855A (en) | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4543256A (en) | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
US4687773A (en) | 1983-03-28 | 1987-08-18 | Mclean Hospital | (+)-N-N-propylnorapomorphine and selective limbic activity |
US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US4980358A (en) * | 1988-04-04 | 1990-12-25 | George D. McAdory | Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function |
US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
US5270323A (en) | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
ATE241984T1 (de) | 1993-03-26 | 2003-06-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin |
ATE189121T1 (de) | 1994-04-22 | 2000-02-15 | Pentech Pharmaceuticals Inc | Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
IL123583A (en) | 1995-10-13 | 2003-07-31 | Neurosearch As | 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them |
-
1998
- 1998-05-29 US US09/086,630 patent/US6403605B1/en not_active Expired - Fee Related
-
1999
- 1999-05-27 AR ARP990102489A patent/AR019579A1/es unknown
- 1999-05-28 AT AT99923347T patent/ATE326969T1/de not_active IP Right Cessation
- 1999-05-28 ES ES99923347T patent/ES2268869T3/es not_active Expired - Lifetime
- 1999-05-28 EP EP99923347A patent/EP1082118B1/en not_active Expired - Lifetime
- 1999-05-28 CA CA002331387A patent/CA2331387A1/en not_active Abandoned
- 1999-05-28 DE DE69931487T patent/DE69931487T2/de not_active Expired - Fee Related
- 1999-05-28 AU AU40272/99A patent/AU764009B2/en not_active Ceased
- 1999-05-28 WO PCT/CA1999/000508 patent/WO1999062502A2/en active IP Right Grant
- 1999-05-28 EP EP05025295A patent/EP1666040A1/en not_active Withdrawn
- 1999-07-07 TW TW088111525A patent/TWI232748B/zh not_active IP Right Cessation
-
2001
- 2001-09-12 HK HK01106459A patent/HK1037517A1/xx not_active IP Right Cessation
-
2002
- 2002-05-20 US US10/147,904 patent/US20030092725A1/en not_active Abandoned
-
2006
- 2006-06-26 US US11/474,783 patent/US20060281752A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999062502A3 (en) | 2000-06-15 |
US20030092725A1 (en) | 2003-05-15 |
ATE326969T1 (de) | 2006-06-15 |
AU764009B2 (en) | 2003-08-07 |
EP1082118A2 (en) | 2001-03-14 |
ES2268869T3 (es) | 2007-03-16 |
CA2331387A1 (en) | 1999-12-09 |
AR019579A1 (es) | 2002-02-27 |
TWI232748B (en) | 2005-05-21 |
US6403605B1 (en) | 2002-06-11 |
WO1999062502A2 (en) | 1999-12-09 |
DE69931487T2 (de) | 2007-05-03 |
EP1666040A1 (en) | 2006-06-07 |
DE69931487D1 (de) | 2006-06-29 |
EP1082118B1 (en) | 2006-05-24 |
US20060281752A1 (en) | 2006-12-14 |
AU4027299A (en) | 1999-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0106183D0 (en) | Improvements in or relating to the treatment of lesions | |
IL142908A0 (en) | Compounds useful in the treatment of inflammatory diseases | |
HUP0203367A3 (en) | Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes | |
HUP0200549A3 (en) | Apomorphine and sildenafil composition and their use | |
HUP0200442A3 (en) | Azeotrope-like composition comprising 1,1,1,3,3-pentafluorobutane and its use | |
AU5845099A (en) | Use of (pex) in the treatment of metabolic bone diseases | |
IL143410A0 (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males | |
HK1037517A1 (en) | Use of apomorphine in the treatment of premature ejaculation | |
IL127351A0 (en) | Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV | |
HUP0203811A3 (en) | Use of polymeric material in the treatment of hard surfaces | |
GB9912159D0 (en) | Improvements in and relating to the treatment of water | |
GB9816234D0 (en) | Compounds for use in the treatment of inflammation | |
EP1079764A4 (en) | TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS | |
HUP0300339A3 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
AP9901683A0 (en) | Treatment of water | |
AU4676099A (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
IL143413A0 (en) | Method for the activation of water and use thereof | |
EP1328264A4 (en) | USE OF ESTRAMUSTIN PHOSPHATE IN THE TREATMENT OF BONE MEASURES | |
EP1032266A4 (en) | USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS | |
AU3061199A (en) | Skin treatment compositions and the use thereof | |
GB9904252D0 (en) | Composition for the treatment of pain | |
HK1048767A1 (zh) | 治療疼痛的方法和組合物 | |
HK1055288A1 (en) | Novel aqueous composition and use of the same | |
GB9805686D0 (en) | Treatment of metals | |
SI1047428T1 (sl) | Uporaba morfolinola za zdravljenje seksualne disfunkcije |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100528 |